Epidemiology and Biomarker Study in Alzheimer's Disease
Key facts
- Where
- Bunkyō City and Tokyo, JapanSee the 3 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 75 years old?
Source: NCT07142954, who can take part
Where in Japan
- The University of Tokyo HospitalBunkyō City, JapanTaking people
- Higashi Shinjuku ClinicTokyo, JapanTaking people
- Souseikai Sumida HospitalTokyo, JapanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07142954
- Record updated
- 7 July 2026
- Original description
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts.Read full original descriptionShow less
A Longitudinal, Prospective Epidemiology Study in Alzheimer's Disease: Assessing Neurocognitive and Biomarker Changes and Health Outcomes in Individuals at Risk for Symptoms of Alzheimer's Disease (ANCHOR-AD)
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts.
Participation in AACU will last approximately 7 years.
Inclusion: The participant must self-report unimpaired cognition; The participant must have adequate literacy, vision, and hearing for neuropsychological assessments at the time of screening.
Exclusion: Are currently enrolled or have previously participated in any Alzheimer's Disease (AD)-related study involving an investigational drug intervention; Are currently using or have previously used prescription medications for treatment of mild cognitive impairment (MCI) or dementia such as amyloid targeting therapy (that is, lecanemab, donanemab, aducanumab), cholinesterase inhibitors (for example, benzgalantamine, donepezil, galantamine, rivastigmine), and memantine; Have a history or diagnosis of cognitive impairment, or significant other neurodegenerative disease that can affect cognition; Have seen a doctor about memory concerns.